Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis

Published:2016-11-16 Issue:6 Volume:28 Page:560-566
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Zhuo Yi¹,Lin Lanying²,Zhang Mingwei³

Affiliation:

1. Department of Thoracic Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China

2. Department of Anesthesiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China

3. Department of Radiotherapy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09537104.2016.1246712

Reference48 articles.

1. Facts, rumours and speculations about the mesothelioma epidemic

2. Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center

3. A proposed new International TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest Group

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus Guideline for the Management of Patients with Peritoneal Mesothelioma;2024-04-13

2. Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma;Cancers;2023-12-24

3. Pretreatment Platelet Count is a Prognostic Marker in Lung Cancer: A Danish Registry-based Cohort Study;Clinical Lung Cancer;2023-03

4. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy;Cancer Immunology, Immunotherapy;2023-02-16

5. B. Malignant Pleural Mesothelioma;Airway diseases;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3